Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Measles, Mumps, and Rubella Vaccine Live
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The Measles, Mumps, and Rubella Vaccine Live is a trivalent combination vaccine containing live-attenuated viruses designed to induce active immunity against measles, mumps, and rubella. It typically contains the Schwarz or Edmonston-Zagreb measles strain, the Jeryl Lynn or RIT 4385 mumps strain, and the Wistar RA 27/3 rubella strain. The vaccine works by stimulating the host's immune system to produce neutralizing antibodies and activate cellular immune responses against the respective viral antigens. In the clinical context provided, this vaccine is used as a routine pediatric co-administered intervention in Phase 3 trials (such as NCT03205371) for Sanofi Pasteur's investigational quadrivalent meningococcal conjugate vaccine (MenACYW). These studies evaluate the safety and immunogenicity of the meningococcal vaccine when given concomitantly with standard childhood immunizations to ensure no negative immunological interference occurs.
- Brand names
- M-M-RVaxProTrimovaxM-M-R IIPriorix
- Other names
- MMR vaccineMMRMeasles, Mumps, and Rubella Vaccine live (MMR)
Beyond the preview
Go deeper on Measles, Mumps, and Rubella Vaccine Live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Measles, Mumps, and Rubella Vaccine Live.